

ERENUMAB injection (Aimovig® ▼) for prevention of migraine

The Pan Mersey Area Prescribing Committee recommends the prescribing of ERENUMAB injection (Aimovig® ▼), by specialists only, for prevention of migraine in accordance with NICE TA682.

RED

Erenumab is licensed for prophylaxis of migraine in adults who have at least 4 migraine days per month.¹

NICE technology appraisal TA682² (10 March 2021) recommends erenumab (Aimovig® ▼) as an option for preventing migraine in adults, only if:

- > they have 4 or more migraine days a month
- > at least 3 preventative drug treatments have failed
- > the 140mg dose of erenumab is used **and**
- > the company provides it according to the commercial arrangement.

Treatment should be initiated by a specialist experienced in the diagnosis and treatment of migraine. Prescribing should be retained by the specialist.

Erenumab should be stopped after 12 weeks if:

- > in episodic migraine (fewer than 15 headache days a month) the frequency does not reduce by at least 50%
- > in chronic migraine (15 or more headache days a month, with at least 8 of those having features of migraine) the frequency does not reduce by at least 30%²

For further information on the prevention of migraine, please refer to the following national and local guidance:

- > NICE Clinical Guideline [CG150] [Headaches in over 12s: diagnosis and management](#), updated November 2015.
- > British Association for the Study of Headache [National Headache Management System for Adults](#), 2019.
- > Pan Mersey Area Prescribing Committee [Headache pathway \(adults\)](#), last updated 24 December 2020.

NICE does not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year (or £9,000 per 100,000 population). This is because the technology is a further treatment option and the overall cost of treatment will be similar.

References

1. Novartis. Summary of Product Characteristics: [Aimovig 140mg solution for injection in pre-filled pen](#), 25 August 2020. Accessed 17 December 2020.
2. National Institute for Health and Care Excellence. Technology appraisal guidance [TA682]: [Erenumab for preventing migraine](#), 10 March 2021. Accessed 23 March 2021.

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.